Last updated: February 16, 2026
What is the Drug NDC 42799-0110?
NDC 42799-0110 refers to Ropidoxuridine, an investigational or proprietary drug used in specific cancer treatments. It is identified through the National Drug Code (NDC) system and is listed under the category of chemotherapeutic agents. As an unapproved or limited-distribution product, comprehensive market data is limited; its primary relevance lies in niche oncology indications and experimental therapy settings [1].
What is the Current Market Landscape?
Market Size and Demand:
- The global cancer therapy market valued approximately USD 150 billion in 2022.
- Ropidoxuridine's specific niche targets gliomas, brain tumors, and certain metastatic cancers—markets with high unmet need but limited current treatment options.
- Relative market penetration is minimal due to recent clinical development stages and lack of FDA approval.
Competitors & Market Share:
- The drug contends with established chemotherapeutics such as temozolomide and temsirolimus for glioma and brain tumor indications.
- No significant market share exists before approval; potential depends heavily on clinical trial outcomes and regulatory decisions.
Regulatory Status:
- Currently in phase 2 trials, with no FDA approval as of the latest data.
- Pending results influence future market potential considerably.
Demand Drivers:
- High unmet needs in brain cancer treatment.
- Potential for expansion into other oncology indications.
- Ongoing clinical trials and investigator-sponsored studies.
What are the Key Price Factors?
Pricing Benchmarks:
- Chemotherapeutic drugs in the US tend to range from USD 5,000 to USD 15,000 per treatment course.
- Experimental agents like Ropidoxuridine are not priced publicly before approval; estimates are based on comparable agents and development stage.
Cost of Development:
- Clinical trial costs for a Phase 2 drug: USD 20 million to USD 50 million.
- Additional costs for regulatory filings, manufacturing scale-up, and market entry.
Pricing Strategy Considerations:
- Likely premium pricing, given niche indication and the high-cost burden of glioma treatments.
- Potential market introduction price estimated between USD 10,000 and USD 25,000 per course, aligning with similar targeted chemotherapies.
What Are Future Price Projections?
| Year |
Estimated Price per Treatment (USD) |
Rationale |
| 2024 |
USD 10,000 - USD 15,000 |
Pre-approval, based on comparable niche drugs |
| 2025 |
USD 15,000 - USD 20,000 |
Post-approval, if clinical outcomes are favorable |
| 2026 |
USD 20,000 - USD 25,000 |
Market penetration increases, patent exclusivity important |
Projection Assumptions:
- FDA approval anticipated in 2024 or 2025, contingent on clinical trial success.
- Market acceptance aligns with improved efficacy over existing therapies.
- Reimbursement codes and insurance coverage influence price realizations.
What Risks and Opportunities Impact the Price?
Risks:
- Clinical trial failures delay or prevent market entry.
- Competition from generics or biosimilars.
- Regulatory delays affect timing and pricing power.
Opportunities:
- Orphan drug designation may enable premium pricing and market exclusivity.
- Label expansion into other cancers increases revenue potential.
Summary of Key Data
- Market size for targeted niche: limited but potentially lucrative.
- Competitive landscape: established chemotherapies dominate; niche products are rare.
- Pricing benchmarks: USD 10,000 to USD 25,000 for treatment courses.
- Future pricing hinges on regulatory approval and clinical success.
Key Takeaways
- Ropidoxuridine’s market remains undefined until regulatory approval and clinical efficacy are confirmed.
- Pricing projections for the first few years post-approval are USD 10,000 to USD 25,000.
- Success depends on clinical outcomes, regulatory timelines, and reimbursement strategies.
- Limited competition in its niche offers high revenue potential if approved and adopted.
- Investment risk remains high; market size is small but can be profitable with strategic positioning.
FAQs
1. What is the primary indication for NDC 42799-0110?
It targets certain brain tumors and metastatic cancers, mainly gliomas, pending clinical validation.
2. How does its pricing compare with existing chemotherapeutics?
It is expected to command a premium, between USD 10,000 to USD 25,000 per treatment course, comparable to other niche, targeted chemotherapies.
3. When is approval likely to be granted?
Based on current clinical trial timelines, potential FDA approval might occur in 2024 or 2025, assuming ongoing studies meet endpoints.
4. What factors influence its market success?
Clinical efficacy, regulatory approval, reimbursement policies, and competitive landscape.
5. What are the risks associated with investing in this drug?
High development costs, clinical failure, regulatory delays, limited market size, and competitive pressures.
References
[1] FDA Drugs@FDA Database, 2023.
[2] MarketResearch.com, "Global Oncology Drugs Market Report," 2022.
[3] IQVIA, "Pharma Cost and Pricing Trends," 2022.
[4] EvaluatePharma, "Cancer Therapeutics Market Outlook," 2022.
[5] ClinicalTrials.gov, "Ongoing Trials for Ropidoxuridine," 2023.
